| S-1 | 2020-08-20 | Public Filing |
| S-1 | 2020-06-15 | Public Filing |
| 10-Q | 2020-04-30 | Filed 2020-06-22 |
| S-1 | 2020-02-18 | Public Filing |
| 10-Q | 2020-01-31 | Filed 2020-03-20 |
| S-1 | 2019-12-12 | Public Filing |
| 10-Q | 2019-10-31 | Filed 2019-12-16 |
| 10-K | 2019-07-31 | Filed 2019-11-12 |
| 10-Q | 2019-04-30 | Filed 2019-06-19 |
| 10-Q | 2019-01-31 | Filed 2019-03-25 |
| 8-K | 2020-08-25 | Enter Agreement, Exhibits |
| 8-K | 2020-08-04 | Enter Agreement, Sale of Shares, Shareholder Rights, Exhibits |
| 8-K | 2020-07-31 | Enter Agreement, Exhibits |
| 8-K | 2020-07-13 | Other Events, Exhibits |
| 8-K | 2020-06-24 | Other Events, Exhibits |
| 8-K | 2020-06-23 | |
| 8-K | 2020-06-22 | |
| 8-K | 2020-06-19 | |
| 8-K | 2020-06-18 | |
| 8-K | 2020-06-17 | |
| 8-K | 2020-06-16 | |
| 8-K | 2020-06-15 | |
| 8-K | 2020-06-11 | |
| 8-K | 2020-06-10 | |
| 8-K | 2020-06-09 | |
| 8-K | 2020-06-08 | |
| 8-K | 2020-06-02 | |
| 8-K | 2020-05-14 | Other Events, Exhibits |
| 8-K | 2020-03-12 | |
| 8-K | 2020-03-03 | |
| 8-K | 2020-02-28 | |
| 8-K | 2020-01-27 | |
| 8-K | 2019-11-22 | |
| 8-K | 2019-11-19 | |
| 8-K | 2019-10-29 | |
| 8-K | 2019-10-28 | |
| 8-K | 2019-10-25 | |
| 8-K | 2019-07-11 | |
| 8-K | 2019-05-06 | |
| 8-K | 2019-04-01 | |
| 8-K | 2019-03-29 | |
| 8-K | 2019-03-25 | |
| 8-K | 2019-02-21 | |
| 8-K | 2019-02-15 | |
| 8-K | 2019-02-13 | |
| 8-K | 2019-02-08 | |
| 8-K | 2019-01-25 | |
| 8-K | 2019-01-24 | |
| 8-K | 2019-01-15 | |
| 8-K | 2019-01-07 | |
| 8-K | 2019-01-07 |
| Comps ($'000 TTM) | Market Cap | Gross Margin | EV/EBITDA | Ret on Assets | Assets | Liabilities | Revenue | G Profit | Net Income | EBITDA | EV |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Rebel Group (REBL) | 0% | 0.0 | -1,380% | 703 | 4,933 | 140 | 0 | -9,708 | -9,660 | -395 | |
| Generex Biotechnology (GNBT) | 21% | 0.0 | -49% | 52,240 | 43,297 | 1,764 | 374 | -25,717 | -18,297 | -540 | |
| Poverty Dignified (POVD) | 0.0 | -4,053% | 49 | 3,080 | 0 | 0 | -2,000 | -1,786 | -41 | ||
| Zhong Ya (WLUC) | 0.0 | 0 | 63 | 0 | 0 | -562 | -562 | -0 | |||
| Weyland Tech (WEYL) | 18% | 2.2 | -24% | 11,699 | 2,218 | 24,630 | 4,372 | -2,779 | -2,702 | -5,821 | |
| Longbau (LNGB) | 4% | -1.0 | 2% | 10,660 | 10,136 | 4,882 | 210 | 165 | 222 | -233 | |
| Scandium International Mining (SCY) | 0.1 | -171% | 957 | 303 | 0 | 0 | -1,636 | -1,634 | -219 | ||
| Aprea Therapeutics (APRE) | 8.4 | -11% | 57,336 | 9,943 | 0 | 0 | -6,249 | -6,249 | -52,334 | ||
| IntelliSense Solutions (INLL) | 0.0 | -7,286% | 2 | 273 | 0 | 0 | -178 | -164 | -2 | ||
| Metropolitan Life Insurance (MLIC) | 0% | -1.8 | 1% | 437,745,000 | 403,121,000 | 37,348,000 | 0 | 4,559,000 | 4,960,000 | -8,986,000 | |
| Zeta Acquisition I (ZETAI) | 0.2 | -649% | 4 | 324 | 0 | 0 | -29 | -18 | -4 | ||
| Ando Holdings (ANDO) | 1.1 | -74% | 73 | 160 | 0 | 0 | -54 | -54 | -61 | ||
| Po Yuen Cultural (POYE) | 0.0 | -1,973% | 1 | 68 | 0 | 0 | -20 | -20 | -0 | ||
| Advanced Biomedical Technologies (ABMT) | 0.0 | -321% | 218 | 6,589 | 0 | 0 | -701 | -701 | -11 | ||
| Kyto Technology & Life Science (KBPH) | 0% | 0.8 | -12% | 2,578 | 66 | 15 | 0 | -315 | -315 | -238 | |
| Federal Home Loan Bank of Topeka (FHLBT) | 29.6 | 0% | 57,131,130 | 54,472,808 | 0 | 0 | 132,964 | 1,095,234 | 32,380,961 | ||
| CNL Healthcare Properties II (CHPII) | 67% | -4.4 | 68,889,100% | 8,277 | 5,549 | -689 | 1,137 | -4,981 | |||
| Original Source Music (OSMU) | 0.0 | 743,400% | 35 | 0 | 0 | -7 | -7 | -0 | |||
| Graham Alternative Investment Fund I (GAIF) | -0.0 | 0% | 29,076 | 1,126 | 0 | 0 | 0 | 5 | -0 | ||
| JiaLiJia Group (RZZN) | 0.0 | -1,721% | 4 | 139 | 0 | 0 | -69 | -69 | -0 |
| Balance Sheet ($'000) | 2019-04-30 | 2019-07-31 | 2019-10-31 |
| Cash | 1,408 | 298 | 540 |
| Accounts Receivable | 1,803 | 36 | 155 |
| Inventory | 250 | 363 | 727 |
| PP&E | 666 | 640 | 769 |
| Assets | 54,036 | 49,636 | 52,240 |
| Accounts Payable | |||
| Long-Term Debt | 530 | 447 | |
| Liabilities | 40,233 | 37,889 | 43,297 |
| Stockholders' Equity | 13,803 | 7,673 | 4,869 |
| Income Statement ($'000) | 2019-04-30 | 2019-07-31 | 2019-10-31 |
| Revenue | 1,093 | -51 | 722 |
| Cost of Revenue | 1,265 | -9 | 134 |
| Gross Profit | -172 | -42 | 588 |
| R&D | 472 | 286 | 339 |
| SG&A | 8,657 | 3,864 | 4,787 |
| Tax | |||
| Net Income | -11,153 | -5,251 | -9,313 |
| Cash Flow ($'000) | 2019-04-30 | 2019-07-31 | 2019-10-31 |
| Cash Operating | -1,516 | -1,844 | |
| Cash Investing | 36 | 45 | |
| Cash Financing | 381 | 2,041 | |